Literature DB >> 11555584

Vascular endothelial growth factor and cellular chemotaxis: a possible autocrine pathway in adult T-cell leukemia cell invasion.

T Hayashibara1, Y Yamada, T Miyanishi, H Mori, T Joh, T Maeda, N Mori, T Maita, S Kamihira, M Tomonaga.   

Abstract

Our previous report (T. Hayashibara et al., Leukemia, 13: 1634-1635, 1999) revealed a possible link between high plasma vascular endothelial growth factor (VEGF) concentration and leukemic cell invasion in adult T-cell leukemia (ATL). However, the biological mechanism of this link has not been elucidated. The purpose of this study was to address that mechanism. Our present observations showed that VEGF mRNA was expressed in ATL cell lines. The corresponding protein was secreted into the extracellular environment, which suggested that the major source of plasma VEGF is ATL cells themselves. More interestingly, all of the cell lines examined were found to express the mRNA and protein for fms-like tyrosine kinase-1 (Flt-1), which is one of the receptors for VEGF. Cytofluorometric analysis demonstrated the VEGF binding potency of these cells. In clinical specimens, expression of VEGF and Flt-1 mRNAs was detected in all (100%) of 11 and 8 (73%) of 11 ATL patients, respectively. Cytofluorometric analysis revealed that VEGF effectively bound only to Flt-1-expressing cells. These findings are highly suggestive of an autocrine pathway involving VEGF operating in ATL. The proliferation of ATL cell lines was not affected by treatment with an anti-VEGF antibody or exogenous VEGF, which indicated that VEGF has no mitogenic effect on ATL cells. In contrast, we made the interesting finding that treatment with exogenous VEGF enhanced the chemotactic activities of some ATL cell lines, which may play a key role in ATL cell invasion. Collectively, these data lead us to propose a possible autocrine mechanism involving VEGF operating by way of Flt-1, in which ATL cells up-regulate their own chemotaxis to facilitate their invasion into various organs.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11555584

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  7 in total

1.  Expression of vascular endothelial growth factor and its receptors KDR and Flt-1 in gastric cancer cells.

Authors:  Hua Zhang; Jian Wu; Lin Meng; Cheng-Chao Shou
Journal:  World J Gastroenterol       Date:  2002-12       Impact factor: 5.742

2.  Tax 1-independent induction of vascular endothelial growth factor in adult T-cell leukemia caused by human T-cell leukemia virus type 1.

Authors:  Karen M Watters; Jonathan Dean; Virginie Gautier; William W Hall; Noreen Sheehy
Journal:  J Virol       Date:  2010-03-17       Impact factor: 5.103

Review 3.  VEGF-targeting therapy for breast cancer.

Authors:  George W Sledge
Journal:  J Mammary Gland Biol Neoplasia       Date:  2005-10       Impact factor: 2.673

Review 4.  Chemotaxis in cancer.

Authors:  Evanthia T Roussos; John S Condeelis; Antonia Patsialou
Journal:  Nat Rev Cancer       Date:  2011-07-22       Impact factor: 60.716

5.  Minimally invasive colon resection for malignant colonic conditions is associated with a transient early increase in plasma sVEGFR1 and a decrease in sVEGFR2 levels after surgery.

Authors:  H M C Shantha Kumara; J C Cabot; A Hoffman; M Luchtefeld; M F Kalady; N Hyman; D Feingold; R Baxter; R L Whelan
Journal:  Surg Endosc       Date:  2009-06-24       Impact factor: 4.584

6.  Vascular endothelial growth factor receptor-1 mediates migration of human colorectal carcinoma cells by activation of Src family kinases.

Authors:  D P Lesslie; J M Summy; N U Parikh; F Fan; J G Trevino; T K Sawyer; C A Metcalf; W C Shakespeare; D J Hicklin; L M Ellis; G E Gallick
Journal:  Br J Cancer       Date:  2006-06-05       Impact factor: 7.640

7.  The geranyl acetophenone tHGA attenuates human bronchial smooth muscle proliferation via inhibition of AKT phosphorylation.

Authors:  Hui Min Yap; Yu Zhao Lee; Hanis Hazeera Harith; Chau Ling Tham; Manraj Singh Cheema; Khozirah Shaari; Daud Ahmad Israf
Journal:  Sci Rep       Date:  2018-11-09       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.